Information Provided By: 
Fly News Breaks for March 7, 2019
KIN
Mar 7, 2019 | 09:15 EDT
Lake Street analyst Brooks O'Neil lowered his price target for Kindred Biosciences to $12 following the company's Q4 results while affirming a Buy rating on the shares. The analyst says that while Mirataz, Kindred's first approved drug, is off to a solid start, he now believes revenue from the drug will be lower than modeled previously. However, the company has a "deep pipeline of attractive drug candidates for the large and growing companion animal medicines space," O'Neil tells investors in a research note.
News For KIN From the Last 2 Days
There are no results for your query KIN
